Please assess the completion status of the following clinical trial:

Trial Title: Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy women aged 18 years or above;~* requesting emergency contraception within 72 h of a single act of unprotected intercourse in the current menstrual cycle;~* having menstrual cycles between 24 and 42 days~* willing to abstain from further acts of unprotected intercourse and;~* available for follow-up over the next 6 weeks.~Exclusion Criteria:~* post-abortion or postpartum and period have not yet returned,~* being on prescription drugs currently~* having unprotected intercourse in this cycle more than 72 hours or more than once before attending the clinic,~* being found pregnant at the time of presentation,~* breastfeeding,~* having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ,~* uncertain about the date of the last menstrual period,~* having used hormonal contraceptive (including EC pill) or NSAID in the current or past one cycle,~* having history of asthma, urticarial or other allergic reactions to piroxicam, aspirin or other NSAIDs,~* having history of ischaemic heart disease in the past one year~* having history of pelvic ulcer disease and/or gastrointestinal bleeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Piroxicam (Type: ACTIVE_COMPARATOR): Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).